Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years in high-risk patient population

NATICK, Mass., and BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced four-year follow-up data from its TAXUS VI clinical trial. The data demonstrated that the safety and efficacy benefits associated with a moderate-release formulation of the TAXUS(R) Express(TM) paclitaxel-eluting stent system -- which is not approved for commercial distribution -- were maintained at four years with no new stent thrombosis reported after two years. Analysis of the data was presented by Professor Eberhard Grube, M.D., Heart Center Siegburg, Germany, the Co- Principal Investigator of the trial. The Company made the announcement at the annual Paris Course on Revascularization (EuroPCR) in Barcelona.

"Even though the moderate-release TAXUS formulation, with an 8-10 fold higher in vitro dose, was never commercialized, the excellent ongoing results in TAXUS VI further demonstrate the margin of safety of the commercial slow- release TAXUS stent now implanted in more than four million patients worldwide," said Paul LaViolette, Boston Scientific Chief Operating Officer. "With no stent thrombosis after two years, a low cardiac death rate, and a low TLR rate, we continue to be impressed with how paclitaxel performs in this high-risk patient population."

"The four-year results from TAXUS VI demonstrate that the safety and efficacy benefits associated with the moderate-release TAXUS paclitaxel- eluting stent system were maintained in patients with complex coronary artery disease at four years," said Professor Grube. "The performance of the TAXUS stent in these patients was extremely impressive when considering the complexity of their disease, including patients with long lesions, small vessels, and those requiring multiple, overlapping stents."

The randomized, double-blind, co
'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:8/19/2014)... 19, 2014  SCILEX Pharmaceuticals, Inc., a company engaged ... for the treatment of pain, announced that it had formed ... Jeff Gudin , Dr. Charles Argoff , ... Vought . SCILEX Chief Executive Officer ... board would greatly assist in the development and commercialization ...
(Date:8/19/2014)... Colo. , Aug. 19, 2014 ... Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), ... rd Annual Meeting of the American Academy ... Acute Care Surgery in Philadelphia, Pennsylvania ... 2014.  The presentation will report results from a ...
(Date:8/19/2014)... 2014 ,Weight Loss- Market Analysis, ... report provides comprehensive insights about phase III pipeline drugs ... of the report is to establish the understanding for ... across the different countries and regions. While the leading ... also provides details on the drug master filings across ...
Breaking Medicine Technology:SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4
(Date:8/20/2014)... August 20, 2014 Blaine Labs®, ... innovative RevitaDERM® Psoriasis Treatment to ease ... with psoriasis. This all-in-one product was created to ... Psoriasis Treatment is powered by coal tar and ... with this effective ingredient. , RevitaDERM® Psoriasis ...
(Date:8/20/2014)... BOSTON As people grow older, they often have ... awaken too early in the morning. In individuals with ... tends to be especially pronounced, often leading to nighttime ... researchers at Beth Israel Deaconess Medical Center (BIDMC) and ... why sleep becomes more fragmented with age. Reported online ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 GBK, ... honor the 2014 Emmy Award Nominees and Presenters at the ... on August 22nd and 23rd in Beverly Hills from 11am ... gifts, refreshments and music by DJ Morgan Hildebrand. , As ... fundraising and will feature several charities at the lounge. GO ...
(Date:8/20/2014)... Kowa Optimed returns after a short ... the new SL-17 portable slit lamp. , The SL-17 ... source controlled by an illuminated thumb wheel for easy ... commercially available AAA rechargeable and dry cell batteries, which ... batteries designed specifically for the device. The new Sl-17 ...
(Date:8/20/2014)... Over 31 million Americans suffer from low back ... pain is the single leading cause of disability worldwide, and ... Americans spend at least $50 billion each year trying to ... pain are not due to organic conditions such as arthritis; ... a busy accountant, had little time for physical activity or ...
Breaking Medicine News(10 mins):Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 2Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 4Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2
... ... Local Academy Offers Training & Education , ... (PRWEB) February 5, 2010 -- During these difficult economic times, we are ... the job to apply for just isn’t there. There is one piece of advice that ...
... , NEW YORK ... (HSS), a world leader in orthopedics and rheumatology, today announced ... launched campaign, "Moving is the Best Medicine," to raise awareness ... , "Like the Arthritis Foundation, we are focusing our extensive ...
... TSX:HAE , MONTREAL , Feb. 5 /PRNewswire-FirstCall/ - ... extension until March 22, 2010 of the delay within ... to make a proposal to its creditors it filed on ... Canada ). This extension is intended to allow Haemacure to complete ...
... , , BEIJING, CHINA , Feb. 5 /PRNewswire-FirstCall/ ... a certain previously released news announcements namely January 7 2009, ... 12,2010 , and January 22, 2010 . , These are significant ... are now starting to crystallize and are beginning to transform HTDS from ...
... in training and bioethicists at Johns Hopkins have created ... quickly assess a patient,s decision-making capacity in an emergency. ... to use it, will be published in the February ... and Communicate, Understand, Reason, Value, Emergency and Surrogate. Doctors ...
... to misuse prescribed drugs, suffer flareups , FRIDAY, ... use herbal remedies experience increased symptoms and poorer quality ... 326 asthma patients for 33 months. Of those patients, ... prescribed inhaled corticosteroids (ICS) less often than other patients. ...
Cached Medicine News:Health News:Addiction Industry Thrives Amidst Economic Climate, Seeks Certified Candidates 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 3Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 2Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 3Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 5Health News:Bioethics memory aid can help assess patient decision-making capacity in medical emergencies 2Health News:Bioethics memory aid can help assess patient decision-making capacity in medical emergencies 3Health News:Herbals Not the Answer for Asthma, Study Shows 2
... ECG Systems offer clinical features to meet ... functionality for paperless storage. Flexible, affordable, and ... PCE Exercise ECG software turns any computer ... with its ability to connect with leading ...
... CardioDirect12-S is the stress testing system from ... turn-key system including treadmill or bicycle ergometer, ... BP option. It uses the same CardioDirect ... resting ECG. ,The system is ...
... Burdick ExTOL systems feature your choice ... multi-channel electrocardiographs, an easy-to-operate monitor and ... ExTOL exercise stress testing systems also ... measurement point, pre-programmed or custom protocols, ...
The Urchin heart positioner provides excellent access to target coronaries while minimizing hemodynamic instability...
Medicine Products: